Application of CK2 inhibitor in preparation of rheumatoid arthritis treatment drugs

A technology for treating drugs and inhibitors, applied in the preparation of rheumatoid arthritis treatment drugs, in the field of CK2 inhibitors, to achieve the effects of convenient treatment, good compatibility, and slowing disease scores

Inactive Publication Date: 2021-01-29
PEOPLES HOSPITAL PEKING UNIV
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Previous studies have shown that CK2 can promote the growth of medulloblastoma in children, the proliferation of endometrial cancer cells, and the growth of castration-resistant prostate cancer cells. Whether CK2 has an impact on the pathogenesis of rheumatoid arthritis is still unclear. no research

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of CK2 inhibitor in preparation of rheumatoid arthritis treatment drugs
  • Application of CK2 inhibitor in preparation of rheumatoid arthritis treatment drugs
  • Application of CK2 inhibitor in preparation of rheumatoid arthritis treatment drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] Example 1 CK2 is involved in the pathogenesis of RA

[0038] Peripheral blood mononuclear cell extraction method steps:

[0039] (1) Collect 8ml of peripheral blood with EDTA-containing anticoagulant sterile blood collection tube;

[0040] (2) Take an equal amount of PBS to dilute peripheral blood (1:1);

[0041] (3) Isolate peripheral blood mononuclear cells (PBMC) according to the instructions of the human peripheral blood mononuclear cell separation medium;

[0042] (4) The expression levels of CK2 subunit α and β proteins in RA patients and HC PBMC were analyzed by western botting detection technology.

[0043] CD4 + T lymphocyte extraction method steps:

[0044] (1) Extract PBMC according to the peripheral blood mononuclear cell extraction procedure;

[0045] (2) Add an equal volume of PBS to wash, 1800rpm, 5 minutes, discard the supernatant;

[0046] (3) Add 200 μl of PBS to resuspend;

[0047] (4) Add 5 μl of FITC-CD4 + T antibody staining in the dark for...

Embodiment 2

[0055]Example 2 The therapeutic effect of CK2 inhibitors on rheumatoid arthritis

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides application of a CK2 inhibitor in the preparation of rheumatoid arthritis treatment drugs. The CK2 inhibitor can significantly slow down disease scores of collagen-induced arthritis (CIA) mice, reduce synovitis and bone erosion degree, has no obvious organ toxicity and side effects, and is suitable for the preparation of rheumatoid arthritis treatment drugs.

Description

technical field [0001] The invention relates to the technical field of treating rheumatoid arthritis, in particular to the application of CK2 inhibitors in the preparation of medicines for treating rheumatoid arthritis. Background technique [0002] Rheumatoid arthritis (RA) is an antigen-driven, T-cell-mediated systemic autoimmune disease that can lead to severe joint deformities and is one of the major disabling diseases. The prevalence rate of rheumatoid arthritis in the world is about 1%. In my country, the prevalence rate of this disease is 0.24%-0.4%, and the number of patients is about 5 million. At present, most patients cannot get their disease under control due to poor curative effect or serious adverse reactions. In the second national sample survey of disabled persons conducted in 2006, disabling joint disease ranked second among the 21 causes of physical disability, of which 79.4% were disabled by rheumatoid arthritis, seriously affecting the quality of life ....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K31/4745A61K31/4192A61K31/4184A61K31/4164A61K31/519A61K31/192A61K31/366A61P29/00A61P19/02A61P19/04A61P19/08
CPCA61K9/0053A61K31/192A61K31/366A61K31/4164A61K31/4184A61K31/4192A61K31/4745A61K31/519A61K45/00A61P19/02A61P19/04A61P19/08A61P29/00
Inventor 叶华胡凡磊付冬冬栗占国
Owner PEOPLES HOSPITAL PEKING UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap